Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3.

Cancer research - 1 Oct 2016

Zhou Ying, Dang Jason, Chang Kung-Yen, Yau Edwin, Aza-Blanc Pedro, Moscat Jorge, Rana Tariq M

Abstract excerpt

Global miRNA functional screens can offer a strategy to identify synthetic lethal interactions in cancer cells that might be exploited therapeutically. In this study, we applied this strategy to identify novel gene interactions in KRAS-mutant cancer cells. In this manner, we discovered miR-1298, a novel miRNA that inhibited the growth of KRAS-driven cells both in vitro and in vivo Using miR-TRAP affinity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Cell Adhesion Molecules

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Focal Adhesion Protein-Tyrosine Kinases

Share to Gene Expression Regulation, Neoplastic

Share to Kalinin

Share to Lung Neoplasms

Share to MicroRNAs

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 27698189
DOI: 10.1158/0008-5472.CAN-15-2936
PMCID: PMC5155639

Genes

KRAS
LAMB3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3.PMID 27698189Read ↗

Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancerSemantic proximity Read ↗

SHANK3 depletion leads to ERK signalling overdose and cell death in KRAS-mutant cancers.Semantic proximity Read ↗

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.Semantic proximity Read ↗

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.Semantic proximity Read ↗

The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer.Semantic proximity Read ↗

Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.Semantic proximity Read ↗

RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer.Semantic proximity Read ↗

Ras-ling with new therapeutic targets for metastasis.Semantic proximity Read ↗

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.Semantic proximity Read ↗

Targeting the c-Met Signaling Pathway in CancerSemantic proximity Read ↗

Daraxonrasib, a pan-RAS inhibitor, selectively inhibits osteosarcomas with activated KRAS by halting AKT signaling and matrix metalloprotease activity.Semantic proximity Read ↗

Furin-like enzyme dependency in KRAS-mutant colorectal cancer as a target for personalized treatment strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.